Eli Lilly Launches Genetic Medicine and RNA-Focused Facility
Eli Lilly has invested $700 million to launch a Boston, Mass., facility focusing on RNA-based therapeutics and genetic medicines.
Called the Lilly Institute for Genetic Medicine, the new site will focus on medicines acting at the nucleic acid level to advance a new class of drugs that target the root cause of diseases, said Andrew C. Adams, Lilly’s vice president of genetic medicine and co-director of the institute.
Genetic medicines already account for 20 percent of Lilly’s diabetes, immunology and central nervous system portfolio, but the goal is to push that further. Lilly says it plans to double the number of research biologists, chemists and data scientists working at the new genetic medicines and RNA-focused site to more than 250 within five years.
February 23, 2022
